RxDoctor Payments Data

Alla Yugay, MD

Pulmonary Disease · Laurel, MSNPI 1649624834

Payments from drug & device makers

$2,410in general payments, 2019–2025

Across 131 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$766
  • Regeneron Healthcare Solutions, Inc.$328
  • Sanofi$266
  • United Therapeutics Corporation$220
  • AstraZeneca$180
  • Insmed, Inc.$165
  • plus $484 from 10 others

What the payments were for

  • Food & beverage$2,36098%
  • Education$502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,410 in reported general payments places this provider in the 35th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$146,400
Medicare patients
422
Services billed
1,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter862$652,439
Breztri AerosphereBudesonide/Glycopyr/Formoterol211$154,954
Dupixent PenDupilumab18$72,847
Humira PenAdalimumab11$67,620
Breo ElliptaFluticasone/Vilanterol125$58,232
EliquisApixaban80$52,441
Dupixent SyringeDupilumab11$40,987
NucalaMepolizumab11$40,577
Albuterol Sulfate HfaAlbuterol Sulfate1,092$38,760
Stiolto RespimatTiotropium Br/Olodaterol Hcl65$32,253
SymbicortBudesonide/Formoterol Fumarate94$30,745
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr64$30,120
Advair HfaFluticasone Propion/Salmeterol48$23,318
Spiriva RespimatTiotropium Bromide26$19,624
Combivent RespimatIpratropium/Albuterol Sulfate29$16,891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta$766$791,6981,084 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$180$192,323321 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$46$68,768120 claims
MerckDulera$14$4,03812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Laurel

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →